RE:RE:RE:RE:RE:RE:RE:Exciting update!!Lol, you obviously haven't been in SVA very long. What a joke regarding your IR analysis. Hahahahaha!!
Stockfshr wrote: Ok, so you do not believe Dr. T is the right person in charge at this point in the company's life cycle. Let's explore that thought. According to the company website, Dr. T has been the President and CEO since April, 2009. While at Sernova, Dr. Toleikis has "secured over $60 million in various forms of financings, including equity raises and multiple non-dilutive grants and has been responsible for negotiating a worldwide exclusive license with UHN and University of Miami for its stem cell derived technologies as well as developing business relationships and or collaborations with multiple pharmaceutical and academic institutions involving its Cell Pouch™ device and cell technologies."
Sounds pretty good so far. But this is all technical stuff. Does Dr. T have any promotional abilities? Maybe not. So what has the company done to mitigate any shortcomings in this regard? Let's see. According to their news release on September 19, 2021 "Sernova Corp. has engaged New York-based LifeSci Advisors LLC, a leading investor relations consultancy firm serving life science companies" and on December 14, 2021 "Sernova Corp. has appointed executive Christopher Barnes as vice-president, investor relations. Mr. Barnes will lead the execution of Sernova's investor relations strategy and communications activities."
Looks to me that they are addressing the promotional activities as well. I am content with their strategy at this point.